Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
This trial is active, not recruiting.
|Treatment||obtain tissue specimens|
|Sponsor||Memorial Sloan Kettering Cancer Center|
|Start date||February 2011|
|End date||February 2017|
|Trial size||30 participants|
|Trial identifier||NCT01300429, 11-014|
The purpose of this study is to try to learn more about how small molecule kinase inhibitor medications work in treating lung cancer. Crizotinib (PF-02341066) is a drug that has been shown to shrink tumors in some patients with lung cancer. While the investigators know how this drug works to stop the growth of tumors that depend on change in the gene named ALK (also called EML4-ALK), the investigators do not know why the drug stops working. The investigators would like to examine the tumor to help us better understand why crizotinib has stopped working as well as it once did. The tumor will be examined with multiple tests to look for the reason that crizotinib stopped working.
the frequency of acquired mutations
time frame: 2 years
Male or female participants at least 18 years old.
Inclusion Criteria: - ≥18 years of age - Histologically proven diagnosis of NSCLC at MSKCC Tumor positive for a translocation or inversion event involving the ALK gene locus - Clinical response to treatment with crizotinib as defined by either: Radiographic partial or complete response defined by RECIST or WHO OR: Radiographic stable disease for at least 8 weeks - Radiographic progression of disease amenable to biopsy while on treatment with crizotinib as defined by RECIST or WHO - Signed informed consent Exclusion Criteria: - Deemed by their treating physician to be medically unfit for biopsy - Women who are pregnant or breast-feeding
|Official title||Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus|
|Principal investigator||Gregory Riely, MD, PhD|
Call for more information